Valisure is a pioneering technology company at the forefront of addressing a critical gap in the healthcare supply chain through independent quality assurance. Our mission is to revolutionize the broken supply chain by providing a critically missing element: transparency to quality and independent certification through chemical analysis. At a time when transparency and reliability have never been more critical, Valisure addresses a significant unmet need, reshaping the future of the healthcare supply chain. Explore collaboration opportunities with us to advance the quality assurance standard in healthcare.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Tellus sapien sed ullamcorper malesuada nulla a, enim tempus. Eget maecenas tortor elementum non.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Tellus sapien sed ullamcorper malesuada nulla a, enim tempus. Eget maecenas tortor elementum non.
Valisure becomes an ISO/IEC 17025:2017 accredited laboratory.
Valisure earns ISO/IEC 17025:2017 laboratory accreditation, validating its testing protocols and operational rigor.
This internationally recognized standard affirms Valisure’s analytical capabilities and commitment to scientific excellence. The team finalizes core testing methodologies and scales lab operations to support the launch of consumer-facing services. With a foundation rooted in validated science, Valisure moves closer to offering the first-ever pharmacy that chemically verifies every batch of medication it dispenses.
Valisure successfully builds and licenses the first online pharmacy that dispenses chemically-validated medications.
Valisure successfully builds and licenses the first online pharmacy that dispenses chemically-validated medications.
With its laboratory accredited and testing protocols fully developed, Valisure launches a groundbreaking model that integrates analytical chemistry into the pharmacy workflow. The company wins Pre-Revenue Venture of the Year at the Connecticut Entrepreneur Awards and publishes its first study in the Journal of Therapeutic Innovation & Regulatory Science, highlighting discrepancies in drug dissolution among common acetaminophen products. These milestones mark Valisure’s emergence as a disruptive force in consumer-focused pharmaceutical quality assurance.
Valisure files its first two FDA Citizen Petitions and has a global impact.
Valisure’s testing uncovers widespread contamination in widely used medications, catalyzing global regulatory action and industry recognition.
Valisure detects the carcinogen DMF in batches of Valsartan, a widely used blood pressure medication, and files its first Citizen Petition with the FDA. Just months later, the company uncovers NDMA, another probable human carcinogen, in ranitidine (Zantac) and nizatidine (Axid), triggering its second petition and leading to international scrutiny.
Valisure's work gains widespread recognition—WIRED Magazine names it one of three companies “fixing the drug industry,” and Senator Chris Murphy presents Valisure with his office’s Innovator Award. By year’s end, over 40 countries take regulatory action based on Valisure’s ranitidine findings, cementing its global impact on pharmaceutical safety.
Valisure’s independent testing and subsequent discoveries generate a growing impact recognized by government and industry.
Valisure’s discoveries fuel national conversations on drug safety and regulatory reform, earning recognition as a disruptor in healthcare.
As Valisure’s discoveries gain traction, the company is invited to join a press conference with Congresswoman Rosa DeLauro to support legislation granting the FDA mandatory recall authority—marking its growing influence in drug policy reform. That same year, Valisure files its third FDA Citizen Petition after detecting the carcinogen NDMA in metformin, a widely used diabetes medication.
Recognized as the first Healthcare Disruptor by MedPage, Valisure becomes a prominent voice in industry conversations, speaking at major conferences including the FDA’s Duke-Margolis think tank, INTERPHEX, and the Virtual Summit on Safe, Effective, High-Quality Medicines. Co-Founder and President David Light testifies before the U.S. Senate Finance Committee, calling for greater oversight in pharmaceutical manufacturing and inspections.
As Valisure continues advancing its mission, GSK publishes a root cause analysis confirming Valisure’s earlier theory on ranitidine’s instability—further validating the company’s scientific leadership and commitment to protecting consumers.
Valisure’s business evolves from direct-to-consumer into enterprise services as impact grows both in drug and consumer products.
Valisure expands beyond pharmacy to become a key enterprise partner in consumer and pharmaceutical product safety.
As its impact widens, Valisure transitions from a direct-to-consumer model to a broader enterprise strategy, selling its pharmacy business and partnering with Medly Pharmacy to expand access to certified medications. The company’s focus shifts to large-scale testing, policy advocacy, and industry collaboration.
Valisure’s testing uncovers benzene, a known carcinogen, in a range of everyday products—starting with hand sanitizers, then sunscreens, body sprays, and other personal care items. These findings result in multiple FDA Citizen Petitions, including joint advocacy with GOJO Industries (makers of Purell), ultimately prompting the FDA to withdraw its emergency hand sanitizer policy and later urge industry-wide testing for benzene contamination.
Recognized for its scientific leadership, Valisure presents its research alongside Agilent Technologies and speaks at prominent industry conferences including the Consumer Healthcare Products Association (CHPA) and the Industry Studies Association. With an expanded focus and strengthened influence, Valisure positions itself at the forefront of chemical safety across both healthcare and consumer goods.
Valisure’s enterprise business successfully integrates independent quality assurance into major, national health systems and continues to build engagement throughout healthcare.
Valisure strengthens its role in national healthcare systems, advancing independent quality assurance and scientific credibility across the industry.
As its enterprise business grows, Valisure deepens partnerships with major health systems and continues shaping the national conversation on drug and consumer product safety. The company contributes to several high-impact scientific publications, including studies in Raman Spectroscopy, Circulation, and the Journal of the American Pharmacists Association, covering topics from adulterated pharmaceuticals to pricing, quality, and safety in generics and personal care products.
Valisure’s research on benzene contamination in sunscreens and dry shampoos garners national attention and reinforces its position as a watchdog for consumer safety. Through innovative efforts like crowdsourcing product samples and co-authoring peer-reviewed studies with GOJO Industries, Valisure advances industry understanding of chemical risks in everyday products.
The company joins the End Drug Shortages Alliance, participates in global forums on benzene detection, and is recognized in Bloomberg’s The Big Take for its outsized impact in a slow-moving regulatory landscape. Congressional leaders amplify Valisure’s advocacy by calling on the FDA to take further action on its Citizen Petitions—demonstrating Valisure’s growing influence in shaping policy and protecting public health.
Valisure further expands its enterprise footprint with strong US government engagement and partnerships, in addition to expanding services in private healthcare systems.
Valisure deepens its enterprise partnerships and strengthens collaboration with U.S. government agencies to tackle drug quality, safety, and supply chain vulnerabilities.
As concerns over drug quality and shortages intensify, Valisure plays a central role in shaping national responses. The White House engages Valisure as an expert resource in addressing the drug supply crisis, and Congresswoman Rosa DeLauro continues her advocacy by urging the FDA to investigate concerns related to Zantac and industry oversight.
Valisure’s enterprise presence expands through continued partnerships with major healthcare systems like Kaiser Permanente, and it enters into a Cooperative Research and Development Agreement with the Department of Defense, marking a significant step toward integrating independent quality assurance into national healthcare infrastructure. The partnership includes official research efforts at the Uniformed Services University and collaborative work with the U.S. Army to address drug quality as a matter of public health and national security.
CEO David Light speaks at leading forums, including Stanford Medicine Grand Rounds, Bluesight’s Medication Intelligence Summit, the ASMS Mass Spectrometry Conference, and international webinars hosted by Syft Technologies, showcasing Valisure’s scientific contributions and leadership in real-time contamination detection.
In collaboration with Bloomberg, Valisure investigates global cough syrup contamination, identifying ethylene glycolin cold medications. This leads to alerts issued by the World Health Organization and widespread international recalls—underscoring Valisure’s role in consumer safety beyond U.S. borders.
The year closes with policy impact: the FDA issues guidance to reformulate products using “carbomer” gelling agents—a direct response to Valisure’s research and petition calling out the risk of benzene contamination in common drug and cosmetic formulations.
Valisure strengthened its leadership in the growing field of independent quality assurance, marked by strategic investments, groundbreaking studies, and impactful collaborations both in industry and government.
Valisure strengthens its leadership in independent quality assurance through strategic investment, scientific discovery, and high-impact collaboration across healthcare and government.
In a transformative year, Valisure secured significant backing from top healthcare investors, led by AlleyCorp, to accelerate innovation and scale operations. This momentum culminated in the opening of a state-of-the-art laboratory in New Haven, Connecticut, celebrated with a ribbon-cutting event attended by Senator Richard Blumenthal and Congresswoman Rosa DeLauro—marking a new chapter in pharmaceutical quality assurance.
Valisure continued to shape national dialogue by holding a high-level meeting with FDA leadership to present its evolving role in the healthcare ecosystem and advocate for systemic integration of independent testing. The company also expanded its work with the U.S. Department of Defense, launching pilot studies and presenting findings at the Uniformed Services University Military Health System Symposium, as well as before the Senate Armed Forces Committee.
Breakthrough research published in Environmental Health Perspectives and the Journal of Investigative Dermatology confirmed the instability of benzoyl peroxide (BPO) in acne products and its potential to form benzene, a known human carcinogen. The findings prompted wide media coverage and led to a joint press conference with Senator Blumenthal, who subsequently called on the FDA for regulatory action.
Valisure’s leadership was recognized on national stages, with expert presentations at AHRMM, APHA, and the Austin Healthcare Council, addressing urgent issues in drug quality, supply chain transparency, and national security. The company also launched an independent certification initiative for injectable drugs in partnership with Picket Pharmaceuticals, setting new standards for trust and transparency in critical medication sourcing.
Valisure sees the gap of independent testing as an opportunity, and the journey has been very personal. Founders Adam Clark-Joseph and David Light, friends since their Yale days, reconnected after Adam suffered severe complications from his anticonvulsant medication due to batch variability. Shocked by the vulnerability of the existing drug supply chain, they began to grasp the magnitude and pervasiveness of the problem throughout the pharmaceutical industry. Working together to bring a team of like-minded scientists and pharmacy experts to create Valisure, they founded a company dedicated to bringing improvements in quality and consistency to consumers and the overall healthcare industry.
Learn More
